NWP06, an Extended-Release Oral Suspension of Methylphenidate, Improved Attention-Deficit/Hyperactivity Disorder Symptoms Compared with Placebo in a Laboratory Classroom Study
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The purpose of this study was to determine the efficacy of NWP06, a novel extended-release (ER) liquid formulation of methylphenidate (MPH), compared with placebo in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children in a laboratory school. METHODS: A total of 45 subjects ages 6-12 years were enrolled in this dose-optimized, randomized, double-blind, placebo-controlled, crossover laboratory school study. Following open-label dose optimization, subjects received 2 weeks of double-blind treatment (1 week of NWP06 and 1 week of placebo). The treatment sequence (NWP06/placebo or placebo/NWP06) was randomly assigned with the last day of each week-long treatment occurring on the laboratory school test day. Efficacy measures included Swanson, Kotkin, Agler, M-Flynn and Pelham (SKAMP) Rating Scale-Combined and Permanent Product Measure of Performance (PERMP) mathematics tests measured at pre-dose and at 0.75, 2, 4, 8, 10, and 12 hours post-dose on each laboratory classroom day. Safety assessments included physical examination, screening electrocardiogram (ECG), vital signs, clinical laboratory tests, adverse event measures, and assessment of suicidality with the Columbia Suicide Severity Rating Scale. RESULTS: NWP06 resulted in significant (p<0.0001) improvements in the SKAMP-Combined score at 4 hours post-dose (mean=7.12) as compared with placebo (mean=19.58) in the completers (n=39). Significant separation from placebo occurred at each time point tested (0.75, 2, 4, 8, 10, 12 hours), with onset of action of NWP06 at 45 minutes post-dose and duration of efficacy extending to 12 hours post-dose. Adverse events (AEs) and changes in vital signs following NWP06 treatment were generally mild and consistent with the known safety profile of MPH. The most common AEs in the open-label phase were decreased appetite (55.6%), upper abdominal pain (42.2%), affect lability (26.7%), initial insomnia (22.2%), insomnia (17.8%), and headache (17.8%). CONCLUSIONS: NWP06 treatment effectively reduced symptoms of ADHD in children beginning at 45 minutes and continuing for 12 hours post-dose. NWP06 was well tolerated. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00904670. http://www.clinicaltrials.gov/ct2/show/NCT00904670 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subcommittee on Attention-Deficit/Hyperactivity Disorder, S. C. O. Q. I. A. M. (2011) · Pediatrics · doi:10.1542/peds.2011-2654 · Cited by 2,185
Pliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765
Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis
Faraone, S. V., & Buitelaar, J. (2010) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-009-0054-3 · Cited by 485 · cited 2×
“…the SKAMP-combined score at 4 hours post-dose, was statistically significantly lower with NWP06 treatment compared with placebo treatment, and the large effect size observed (2.5) is in line with effect sizes observed for other stimulants in the treatment of ADHD (Faraone and Buitelaar 2010).”
ResultInfluentialBiederman, J., Boellner, S. W., Childress, A., Lopez, F. A., Krishnan, S., & Zhang, Y. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.015 · Cited by 360 · cited 2×
“…oral stimulants have demonstrated a range in both onset and duration of effect as measured in laboratory classroom studies (McCracken et al. 2003; Swanson et al. 2004; Silva et al. 2006; Biederman et al. 2007; Brams et al. 2008; Silva et al. 2008; Wigal et al. 2009, 2011; Armstrong et al. 2012).”
BackgroundSelf-citationSwanson, J. M., Wigal, S. B., Wigal, T., Sonuga-Barke, E., Greenhill, L. L., Biederman, J., Kollins, S., Nguyen, A. S., DeCory, H. H., Hirshe Dirksen, S. J., et al. (2004) · Pediatrics · doi:10.1542/peds.113.3.e206 · Cited by 238
Self-citationMCCRACKEN, J. T., BIEDERMAN, J., GREENHILL, L. L., SWANSON, J. M., MCGOUGH, J. J., SPENCER, T. J., POSNER, K., WIGAL, S., PATAKI, C., ZHANG, Y., et al. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000046863.56865.fe · Cited by 116 · cited 2×
“…available long-acting oral stimulants have demonstrated a range in both onset and duration of effect as measured in laboratory classroom studies (McCracken et al. 2003; Swanson et al. 2004; Silva et al. 2006; Biederman et al. 2007; Brams et al. 2008; Silva et al. 2008; Wigal et al. 2009, 2011;…”
BackgroundSelf-citationthe 311 Study Group, Wigal, S. B., Kollins, S. H., Childress, A. C., & Squires, L. (2009) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-3-17 · Cited by 110
Self-citationSilva, R. R., Muniz, R., Pestreich, L., Childress, A., Brams, M., Lopez, F. A., & Wang, J. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.239 · Cited by 44 · cited 1×
“…oral stimulants have demonstrated a range in both onset and duration of effect as measured in laboratory classroom studies (McCracken et al. 2003; Swanson et al. 2004; Silva et al. 2006; Biederman et al. 2007; Brams et al. 2008; Silva et al. 2008; Wigal et al. 2009, 2011; Armstrong et al. 2012).”
BackgroundSelf-citationEffect Size of Lisdexamfetamine Dimesylate in Adults with Attention-Deficit/Hyperactivity Disorder
Wigal, T., Brams, M., Gasior, M., Gao, J., & Giblin, J. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.03.2275 · Cited by 16
Cited by
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Storebø, O. J., Ramstad, E., Krogh, H. B., Nilausen, T. D., Skoog, M., Holmskov, M., Rosendal, S., Groth, C., Magnusson, F. L., Moreira-Maia, C. R., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009885.pub2 · Cited by 347
Storebø, O. J., Pedersen, N., Ramstad, E., Kielsholm, M. L., Nielsen, S. S., Krogh, H. B., Moreira-Maia, C. R., Magnusson, F. L., Holmskov, M., Gerner, T., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012069.pub2 · Cited by 321
Pozzi, M., Carnovale, C., Peeters, G. G. A. M., Gentili, M., Antoniazzi, S., Radice, S., Clementi, E., & Nobile, M. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.05.021 · Cited by 56
Metadata
- Authors
- Wigal, S. B., Childress, A. C., Belden, H. W., & Berry, S. A.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2013-02
- Volume
- 23
- Issue
- 1
- Pages
- 3-10
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2023049165
- Cited by
- 49
- References
- 9
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: NWP06, an Extended-Release Oral Suspension of Methylphenidate, Improved Attention-Deficit/Hyperactivity Disorder Symptoms Compared with Placebo in a Laboratory Classroom Study. https://app.cochat.ai/papers/10.1089/cap.2012.0073
- The paper
- Wigal, S. B., Childress, A. C., Belden, H. W., & Berry, S. A. (2013). NWP06, an Extended-Release Oral Suspension of Methylphenidate, Improved Attention-Deficit/Hyperactivity Disorder Symptoms Compared with Placebo in a Laboratory Classroom Study. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2012.0073
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.